Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company
- None.
- None.
The announcement from Dyadic International regarding the signing of a fully funded evaluation agreement with a leading biopharmaceutical company signifies a pivotal development for the company. The agreement to utilize Dyadic's C1 microbial protein production platform for recombinant proteins highlights the platform's potential in addressing needs within the biopharmaceutical industry. This collaboration could lead to increased validation of Dyadic's technology, potentially accelerating its adoption for the production of biologics, including vaccines and antibodies.
From a biotechnology perspective, the C1 platform's ability to produce recombinant proteins more efficiently than traditional systems could result in reduced costs and faster development times for therapeutics and vaccines. This efficiency gain is critical in a market where rapid response to infectious diseases is increasingly important. If Dyadic's platform demonstrates success in producing effective biopharmaceuticals, it could attract additional partnerships, thereby expanding its market presence and potentially increasing shareholder value.
The financial implications of this agreement for Dyadic International are multifaceted. A fully funded evaluation agreement implies that the R&D costs associated with the use of the C1 platform will not burden Dyadic, which is favorable for the company's financial health. Furthermore, the inclusion of a commercial option suggests a pathway to future revenue streams, contingent on the successful application of the technology. The market's response to such announcements can be positive, reflecting in the company's stock performance, especially if the partnering entity is a major player in the biopharmaceutical field.
Investors should monitor the progress of this partnership closely, as successful outcomes from the use of the C1 platform could lead to upward revisions in revenue forecasts and potentially enhance the company's valuation. Moreover, the 'positive Phase I first in human data' for a recombinant vaccine produced using the C1 platform, as mentioned by the CEO, provides a tangible proof of concept that could reduce investment risk perceptions associated with the company's technology.
The strategic move by Dyadic to increase global outreach and build an active pipeline through its proprietary microbial platform technologies aligns with the current trends in the biopharmaceutical sector. The demand for recombinant proteins, which are used in a variety of therapeutic applications, is growing. The ability of Dyadic's C1 platform to potentially streamline the production process positions the company to capitalize on this market demand. The production of recombinant human and bovine albumin, vaccines and other biologic products has substantial market potential, given their wide-ranging applications in medical treatments and research.
Understanding the competitive landscape is crucial, as there are other companies with alternative protein expression systems. Dyadic's success in penetrating the market will depend on the comparative advantages of the C1 platform in terms of production yield, cost-effectiveness and scalability. If Dyadic's technology proves superior or complementary to existing technologies, it could secure a significant market share and establish long-term strategic partnerships within the biopharmaceutical industry.
JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform. Under the agreement, research and development activities will be funded by the collaborator.
“Dyadic's C1 protein expression platform is gaining increased traction in research and development targeting infectious and other diseases,” said CEO Mark Emalfarb, "We are glad to see the progress of our C1-cell protein production platform for human and animal biopharmaceuticals and we believe the recent positive Phase I first in human data for a recombinant vaccine produced using C1 will spark further interest in the adoption of Dyadic’s C1 technology.”
Dyadic is committed to enabling its partners and collaborators in the development of effective preventative and therapeutic treatments globally. Dyadic is increasing global outreach to fulfill its mission to make a difference in global health by building an active pipeline through advancing its proprietary microbial platform technologies to create needed products such as recombinant human and bovine albumin and other biologic vaccines, antibodies, and products.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit https://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
